Bebtelovimab
Based on 1 publication(s) in Google Scholar
Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.41%
- CAS. Nr.: 2578319-11-4
- Molecular Weight:143.82 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Bebtelovimab
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
SARS-CoV-2
In Vitro
Bebtelovimab (1 h) effectively neutralizes authentic SARS-CoV-2/MT020880.1 virus with IC50 values ranging from 9-22.1 ng/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
YP_009724390.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2578319-11-4
-
Appearance Liquid
-
Molecular Weight 143.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Bebtelovimab]
-
Synonyms
LY-3853113; LY-COV1404
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Reinheit & Dokumentation
-
Data Sheet (258 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106(10):e463-e464. [Content Brief]
[2]. Bebtelovimab. IMGT/mAb-DB.
[3]. Westendorf K, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv [Preprint]. 2022 Mar 24:2021.04.30.442182. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)